Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MJFF grants AFFiRiS $1.5m to study PD vaccine
The vaccine targets and eliminates the alpha-synuclein protein, whose clumping is a sign of PD. PD01 vaccine has shown to stimulate the immune system to release antibodies that
The vaccine targets and eliminates the alpha-synuclein protein, whose clumping is a sign of PD. PD01 vaccine has shown to stimulate the immune system to release antibodies that
The patent specifically covers the company’s RX-8243 which is currently in pre-clinical development. According to the company, RX-8243 has demonstrated potent anti-tumor properties in many cancer cell lines,
Alpha-2b incorporates the company’s Biphasix drug delivery technology and provides a better means of delivering interferon-alpha-2b therapeutically to human papillomavirus (HPV) infected tissues. FDA will take 30 days
Under the agreement, which spans over 18 months, the companies will analyse the genomes of patients to search for sequence variants to gain further insights into drug targets.
The Ramsell Care Continuum is an integrated solution developed specifically for an ADAP program to address the needs of HIV/AIDS patients. The Ramsell Care Continuum features a software
GMI-1070 is a pan-selectin antagonist currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease. GMI-1070, which is believed to inhibit selectin
The grant is intended to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. GSK2118436 is an investigational drug that is orally
MM-121 is a fully human monoclonal antibody that targets ErbB3. The Phase 2 study will assess efficacy of MM-121 in combination with paclitaxel as compared to treatment with
The study MODERN [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen] or A4001095 will test the efficacy of Celsentri/Selzentry (maraviroc) versus emtricitabine/tenofovir (Truvada), both
The move in this direction has been made on the back of growing potential in the Brazilian pharma market. Celesio CEO Markus Pinger said Brazil’s healthcare market grows